X4 Pharmaceuticals, Inc
XFOR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001501697
In the last 90 days, X4 Pharmaceuticals, Inc insiders filed 0 open-market purchases and 3 sales; 89 institutions reported holding it in 13F filings for Q2 2026, worth $463.0M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in X4 Pharmaceuticals, Inc as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 99
- +1 vs. Q1 2024
- Shares held
- 101.5M
- −1.46M (−1.4%) vs. Q1 2024
- Total value
- $58.9M
- −$84.2M (−58.8%) vs. Q1 2024
- New holders
- 18
- 36 more added
- Sold out
- 17
- 19 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XFOR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 89 | $463.0M |
| Q1 2026 | 84 | $388.1M |
| Q4 2025 | 79 | $357.7M |
| Q3 2025 | 42 | $55.3M |
| Q2 2025 | 52 | $5.33M |
| Q1 2025 | 94 | $23.3M |
| Q4 2024 | 90 | $73.2M |
| Q3 2024 | 98 | $67.3M |
| Q2 2024 | 99 | $58.9M |
| Q1 2024 | 98 | $143.2M |
| Q4 2023 | 93 | $81.2M |
| Q3 2023 | 91 | $122.6M |
| Q2 2023 | 96 | $219.1M |
| Q1 2023 | 59 | $53.6M |
| Q4 2022 | 54 | $60.2M |
| Q3 2022 | 59 | $66.9M |
| Q2 2022 | 51 | $15.5M |
| Q1 2022 | 56 | $28.6M |
| Q4 2021 | 52 | $40.2M |
| Q3 2021 | 52 | $85.7M |
| Q2 2021 | 63 | $107.8M |
| Q1 2021 | 61 | $138.7M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding X4 Pharmaceuticals, Inc; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Propel Bio Management, LLC | 0 | $0 | 0.00% | −535,000−100.0% | Sold out |
| Simplify Asset Management Inc. | 0 | $0 | 0.00% | −400,000−100.0% | Sold out |
| Royce & Associates LP | 0 | $0 | 0.00% | −342,363−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −321,021−100.0% | Sold out |
| Lighthouse Investment Partners, LLC | 0 | $0 | 0.00% | −70,422−100.0% | Sold out |
| Amundi | 0 | $0 | 0.00% | −81,305−100.0% | Sold out |
| American International Group, Inc. | 0 | $0 | 0.00% | −61,735−100.0% | Sold out |
| Dimensional Fund Advisors LP | 0 | $0 | 0.00% | −55,296−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −47,573−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −29,507−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −20,822−100.0% | Sold out |
| Grimes & Company, Inc. | 0 | $0 | 0.00% | −15,000−100.0% | Sold out |
| Total Clarity Wealth Management, Inc. | 0 | $0 | 0.00% | −13,681−100.0% | Sold out |
| Boston Private Wealth LLC | 0 | $0 | 0.00% | −13,000−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −469−100.0% | Sold out |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 0 | $0 | 0.00% | −22−100.0% | Sold out |